Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Clinical Immunology (Orlando, Fla.)|August 16, 2022
Immunologic and dose dependent effects of rapamycin and its evolving role in chemopreventionAnne E O'Shea, Franklin A Valdera, Daniel Ensley, et al.Cancer Research|August 19, 2017
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic CellsVictor A Gall, Anne V Philips, Na Qiao, et al.Frontiers in Immunology|March 24, 2023
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trialsPatrick M McCarthy, Franklin A Valdera, Todd R Smolinsky, et al.Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.Journal of Surgical Oncology|October 6, 2023
Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing mattersFranklin A Valdera, Anne E O'Shea, Todd R Smolinsky, et al.Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.Pageof 5